Financings
Burrill & Co. raised $300 million for Capital Fund IV and expects to boost it to $500 million.
Neurocrine Biosciences Inc. raised $77 million in a public stock offering.
RaNA Therapeutics Inc. raised $20.7 million in Series A funding to study long noncoding RNA.
Vitae Pharmaceuticals Inc. obtained $15 million in debt financing.
Deals
Constellation Pharmaceuticals Inc. signed a $95 million epigenetics deal with Roche AG.
DARA BioSciences Inc. acquired Oncogenerix Inc. and breast cancer drug Soltamox (liquid tamoxifen)
Valeant Pharmaceuticals International Inc. raised its ISTA Pharmaceuticals Inc. bid to $360 million.
XOMA Corp. bought hypertension drug Aceon (perindopril erbumine) from Les Laboratoires Servier SA.
. . . And More
AstraZeneca plc and Bristol-Myers Squibb Co. got a complete response letter for dapagliflozin in diabetes.
Bristol-Myers Squibb Co. published Phase IIa data showing hepatitis C can be cured without interferon.
BTG plc won FDA approval for Voraxaze (glucarpidase), an antidote to the chemotherapy methotrexate.
Medivation Inc.'s Dimebon (laterpirdine) failed another Phase III Alzheimer's trial and finally got dumped.
NovaDel Pharma Inc. will not have enough cash to meet working capital needs after the end of January.
Onyx Pharmaceuticals Inc. and Bayer AG's regorafenib got good Phase III colorectal cancer data.
Takeda Pharmaceutical Co. Ltd. plans to consolidate its global work force by about 2,800 positions.